Notice on counterfeit medicinal product Norditropin SimpleXx 10 mg/1,5 solution for injection on the market of Bosnia & Herzegovina
The Agency for Medicinal Products and Medical Devices (HALMED) has received a notice from Novo Nordisk Croatia d.o.o. on the suspected counterfeit of Norditropin SimpleXx 10 mg/1.5 ml solution for injection (somatropin) on the market of Bosnia & Herzegovina. The following batches are affected by this suspected counterfeit: SC11255, expiry date 11/2016 and the batch CL70711, expiry date 08/2017. These batches are labelled in the Romanian language.
Based on the manufacturer’s investigation, Novo Nordisk, Denmark, these batches are not manufactured and released by this manufacturer and the suspected counterfeit has been confirmed.
All wholesalers and pharmacies are being warned to pay special attention when receiving medicinal products susceptible to counterfeiting and when selecting a supplier to check whether the holds to the good distribution practice and possesses a wholesale distribution license.
Also, patients who have procured their Norditropin SimpleXx in Bosnia & Herzegovina are warned to pay special attention to the batch they received.
More information is accessible under the link below.